Overview

Estrogen Variability and Irritability During the Menopause Transition

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Women in the menopause transition (perimenopause) experience substantial day-to-day variability in estradiol and have a 2-4-fold increase in major depression risk. About 40% of perimenopausal women are susceptible to the emergence of affective symptoms tied to changes in estradiol. Among the perimenopausal women with affective impairment, most report irritability, not "depression," is their primary source of impairment and distress. The purpose of this research is to determine the neurophysiologic basis of susceptibility to estradiol fluctuations and irritability symptoms in perimenopausal women.
Phase:
Phase 4
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Estradiol
Progesterone